Login or create an account to see restricted contentLogin or Register
The observation that some traditional classes of glucose-lowering agents may have contributed to elevated CV risk prompted regulatory agencies to mandate that new diabetes drugs demonstrate CV safety in dedicated, long-term, placebo controlled CV outcome trials. Evidence from some recent cardiovascular outcome trials has shown improved CV outcomes over and above existing therapies for CV risk factor control.
The DECLARE-TIMI 58 CVOT assessed the cardiovascular safety of dapagli
This module summarises reported DPP-4 inhibitor CVOTs for saxagliptin
Evaluating the CV and kidney safety profile of linagliptin versus
The Harmony Outcomes CVOT assessed the cardiovascular safety of albi
The CREDENCE cardio-renal outcomes trial investigated the effect of ca
This module outlines CVOTs for empagliflozin (EMPA-REG OUTCOME®